CLRB Insider Trading Activity and SEC Form 4 Filings
CLRB insider trading summary
Over the past 12 months, insiders at Cellectar Biosciences, Inc. (CLRB) reported 2 open-market purchases worth $50K by 2 insiders and 1 sale worth $732 by 1 insider on SEC Form 4. Net insider buying was $49K.
Latest CLRB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 7, 2026 | Jarrod Longcor | Chief Operating Officer | Buy | $25K (8,680 @ $2.88) |
| May 7, 2026 | James V Caruso | Chief Executive Officer | Buy | $25K (8,680 @ $2.88) |
| Dec 12, 2025 | John Neis | Director | Sell | $732 (198 @ $3.70) |
| Jul 2, 2025 | James V Caruso | Chief Executive Officer | Buy | $50K (10,000 @ $4.99) |
| Jul 2, 2025 | Jarrod Longcor | Chief Operating Officer | Buy | $50K (10,000 @ $4.99) |
| Jul 2, 2025 | Chad J Kolean | Chief Financial Officer | Buy | $25K (5,000 @ $4.99) |
| Jan 10, 2025 | Jarrod Longcor | Chief Operating Officer | Buy | $8K (30,000 @ $0.28) |
| Sep 14, 2021 | Douglas J Swirsky | Director | Buy | $26K (25,000 @ $1.04) |
| Sep 3, 2021 | Frederick W Driscoll | Director | Buy | $20K (19,417 @ $1.04) |
| Mar 4, 2021 | James V Caruso | President and CEO | Buy | $9K (5,100 @ $1.70) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.